Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Novel approaches to identify cellular vulnerabilities in TET2-dependent MDS

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAtsushi MarumoFSFelipe de Almeida SartoriKLKartik Lakhotiya

Discussion

Loading...

Member takes

Overview

Analysis reveals nonsense mutations impact drug sensitivity in TET2-mutated patients, suggesting new treatment strategies.

Key Points

  • Drug response profiles are similar in patients with nonsense mutations and frameshift mutations.
  • More than 3500 patients were analyzed, identifying distinct TET2 clusters with various mutation types.
  • High throughput screening was employed with 20 human specimens to assess drug sensitivity profiles.
  • Identification of genomic sub-entities may predict novel drug responsiveness and improve treatment outcomes.

Cite This Study

Marumo et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d83ehttps://doi.org/10.1182/blood-2025-3838
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single-cell multiomic profiling of gene mutation, chromatin accessibility, and gene expression in TET2-mutant clonal hematopoiesis2025
  2. 2Bi-allelic TET2 alterations are frequently found in NPM1 mutated AML and constitute a distinct subgroup with unfavorable prognosis2025 · 2 citations
  3. 3Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia2025
  4. 4Beyond clonal hematopoiesis of indeterminate potential: Understanding how the trisomy 21 context promotes TET2 mutations2025
  5. 5Spatial transcriptomic dissection of the myeloproliferative neoplasm niche uncovers mutant clone interactions and microenvironmental rewiring2025